X0206 3 2015-06-24 0 0001454789 CATABASIS PHARMACEUTICALS INC CATB 0001644160 SVLSF V, LLC ONE BOSTON PLACE 201 WASHINGTON STREET SUITE 3900 BOSTON MA 02108 0 0 1 0 0001644146 SV Life Sciences Fund V (GP), LP ONE BOSTON PLACE 201 WASHINGTON STREET SUITE 3900 BOSTON MA 02108 0 0 1 0 0001460732 SV LIFE SCIENCES FUND V LP ONE BOSTON PLACE 201 WASHINGTON STREET SUITE 3900 BOSTON MA 02108 0 0 1 0 0001482194 SV Life Sciences Fund V Strategic Partners, L.P. ONE BOSTON PLACE 201 WASHINGTON STREET SUITE 3900 BOSTON MA 02108 0 0 1 0 Series A Preferred Stock Common Stock 1651223 I See Footnotes Series A Preferred Stock Common Stock 34893 I See Footnotes Series B Preferred Stock Common Stock 764309 I See Footnotes Series B Preferred Stock Common Stock 16152 I See Footnotes The Series A Preferred Stock is convertible into Common Stock on a 1-for-12.85 basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. The Series B Preferred Stock is convertible into Common Stock on a 1-for-12.85 basis into the number of shares shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering without payment of further consideration. The shares have no expiration date. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V LP except to the extent of any pecuniary interest therein. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V SPP except to the extent of any pecuniary interest therein. SVLS V LP and SVLS V SPP (each a "Fund," or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein. Exhibit Index: 24.1 Power of Attorney By: /s/ Denise Marks, Member of SVLSF V, LLC 2015-06-24 By: /s/ Denise Marks, Member of SVLSF V, LLC, general partner of SV Life Sciences Fund V (GP), L.P. 2015-06-24 By: /s/ Denise Marks, Member of SVLSF V, LLC, general partner of SV Life Sciences Fund V (GP), L.P., general partner of SV Life Sciences Fund V, L.P. 2015-06-24 By: /s/ Denise Marks, Member of SVLSF V, LLC, general partner of SV Life Sciences Fund V (GP), L.P., general partner of SV Life Sciences Fund V Strategic Partners, L.P. 2015-06-24